Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H28N2O2 |
Molecular Weight | 424.5341 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C4=CC=CC=C4
InChI
InChIKey=UFIVBRCCIRTJTN-UHFFFAOYSA-N
InChI=1S/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)
Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a brand mixture which combines atropine sulfate and difenoxin hydrochloride. It is approved by the FDA to treat acute and chronic diarrhea. Difenoxin is an active metabolite of the anti-diarrheal drug, diphenoxylate, which is also used in combination with atropine in the brand mixture Lomotil(R). It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). Difenoxin is also closely related to loperamide, but unlike loperamide it is still capable of crossing the blood brain barrier to produce weak sedative and analgesic effects. However, the antidiarrheal potency of difenoxin is much greater than its CNS effects, which makes it an attractive alternative to other opioids. Motofen(R) is a combination of atropine, an anticholinergic drug, and difenoxin, an antidiarrheal drug. It has been used in many countries for many years as a second line opioid-agonist antidiarrheal, which exists an intermediate between loperamide and paragoric. Diarrhea which is a result of cyclic or diarrhea predominant Inflammatory Bowel Syndrome may not be treated effectively with difenoxin, diphenoxylate, or loperamide. As such, diarrhea and cramping which does not respond to non-centrally acting derivatives or belladonna derivatives such as atropine are often treated with conservative doses of codeine. In patients with acute ulcerative colitis, as induction of toxic megacolon is possible, and thus use of Motofen(R) is cautioned. Motofen(R) has been assigned pregnancy category C by the FDA, and is to be used only when the potential benefits outweigh the potential risk to the fetus. The safety of use during lactation is unknown and thus not recommended. Each five-sided dye free MOTOFEN® tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin
hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine). Difenoxin acts as an antidiarrheal by activating peripheral opioid receptors in the small intestine and thereby inhibiting peristalsis. However, research has suggested that non-opioid receptor pathways exist. This would explain the potent antidiarrheal effects of difenoxin despite only limited opioid action.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
|||
Target ID: GO:0030432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8583364 |
10.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MOTOFEN Approved UseMOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute
exacerbations of chronic functional diarrhea. Launch Date1978 |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 100 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 100 Sources: |
Other AEs: Epigastric distress... Other AEs: Epigastric distress (1 patient) Sources: |
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 15 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 15 Sources: |
Other AEs: Nausea... Other AEs: Nausea (1 patient) Sources: |
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 20 Sources: |
Other AEs: Constipation, Dizziness... Other AEs: Constipation (1 patient) Sources: Dizziness (1 patient) |
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 25 Sources: |
Other AEs: Light headedness... Other AEs: Light headedness (1 patient) Sources: |
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 30 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 30 Sources: |
Other AEs: Vomiting, Dry mouth... Other AEs: Vomiting (1 patient) Sources: Dry mouth (1 patient) |
2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 40 Sources: |
Other AEs: Drowsiness, Headache... Other AEs: Drowsiness (1 patient) Sources: Headache (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Epigastric distress | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 100 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 100 Sources: |
Nausea | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 15 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 15 Sources: |
Constipation | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 20 Sources: |
Dizziness | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 20 Sources: |
Light headedness | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 25 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 25 Sources: |
Dry mouth | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 30 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 30 Sources: |
Vomiting | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 30 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 30 Sources: |
Drowsiness | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 40 Sources: |
Headache | 1 patient | 2 mg multiple, oral (starting) Dose: 2 mg Route: oral Route: multiple Dose: 2 mg Co-administed with:: atropine sulfate(2 tablets) Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: acute nonspecific diarrhea Age Group: adult Population Size: 40 Sources: |
Sample Use Guides
Each five-sided dye free MOTOFEN® tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin
hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine). The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1
tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8
tablets. In the treatment of diarrhea, if clinical improvement is not observed in 48 hours, continued administration of
this type of medication is not recommended. For acute diarrheas and acute exacerbations of functional diarrhea,
treatment beyond 48 hours is usually not necessary.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8583364
Difenoxin decreased the rate of peristalsis in the rat isolated ileum with IC=10.4 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
304
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
DEA NO. |
9168
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
DEA NO. |
9167
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
WHO-ATC |
A07DA04
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
WHO-VATC |
QA07DA04
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
NCI_THESAURUS |
C266
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
||
|
NDF-RT |
N0000178374
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3ZZ5BJ9F2Q
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
DTXSID0022931
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
4534
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
7592
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
878
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
1219019
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
100000083174
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
23024
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
C100010
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201321
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
SUB07123MIG
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
C65381
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
2903
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
DB01501
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
34328
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
3ZZ5BJ9F2Q
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
28782-42-5
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | |||
|
m4425
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
DIFENOXIN
Created by
admin on Fri Dec 15 15:59:39 GMT 2023 , Edited by admin on Fri Dec 15 15:59:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)